STOCK TITAN

Invitation to Presentation of Senzime's Third Quarter 2024 Report

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Senzime (SNZZF) has announced a webcast presentation of its Q3 2024 report scheduled for November 6, 15:00 CET. The report will be published earlier the same day. CEO Philip Siberg will lead the presentation, followed by a Q&A session moderated by Carnegie Investment Bank analyst Klas Palin. The presentation will be conducted in English and last 30 minutes. Participants can submit questions in advance via email to the moderator before 12:00 CET on November 6. The presentation will be available on Senzime's investor relations website.

Senzime (SNZZF) ha annunciato una presentazione in webcast del suo rapporto Q3 2024 programmata per il 6 novembre, alle 15:00 CET. Il rapporto sarà pubblicato in anticipo lo stesso giorno. Il CEO Philip Siberg guiderà la presentazione, seguita da una sessione di domande e risposte moderata dall'analista di Carnegie Investment Bank Klas Palin. La presentazione si svolgerà in inglese e avrà una durata di 30 minuti. I partecipanti possono inviare domande in anticipo via email al moderatore entro le 12:00 CET del 6 novembre. La presentazione sarà disponibile sul sito web delle relazioni con gli investitori di Senzime.

Senzime (SNZZF) ha anunciado una presentación web sobre su informe del tercer trimestre de 2024 programada para el 6 de noviembre a las 15:00 CET. El informe será publicado antes ese mismo día. El CEO Philip Siberg dirigirá la presentación, seguida de una sesión de preguntas y respuestas moderada por el analista de Carnegie Investment Bank Klas Palin. La presentación se llevará a cabo en inglés y durará 30 minutos. Los participantes pueden enviar preguntas con antelación por correo electrónico al moderador antes de las 12:00 CET del 6 de noviembre. La presentación estará disponible en el sitio web de relaciones con inversores de Senzime.

Senzime (SNZZF)는 2024년 3분기 보고서에 대한 웹캐스트 프레젠테이션을 11월 6일 15:00 CET로 예정하고 있다고 발표했습니다. 보고서는 같은 날 더 일찍 발표될 예정입니다. CEO Philip Siberg이 프레젠테이션을 이끌며, 이후 Carnegie Investment Bank의 분석가 Klas Palin이 진행하는 Q&A 세션이 있습니다. 프레젠테이션은 영어로 진행되며 30분 동안 진행됩니다. 참가자들은 11월 6일 12:00 CET 이전에 이메일을 통해 미리 질문을 제출할 수 있습니다. 프레젠테이션은 Senzime의 투자자 관계 웹사이트에서 확인할 수 있습니다.

Senzime (SNZZF) a annoncé une présentation en webdiffusion de son rapport du troisième trimestre 2024 prévue pour le 6 novembre à 15:00 CET. Le rapport sera publié plus tôt dans la même journée. Le PDG Philip Siberg dirigera la présentation, suivie d'une session de questions-réponses modérée par l'analyste de Carnegie Investment Bank Klas Palin. La présentation se déroulera en anglais et durera 30 minutes. Les participants peuvent soumettre des questions à l'avance par e-mail au modérateur avant 12:00 CET le 6 novembre. La présentation sera disponible sur le site web des relations investisseurs de Senzime.

Senzime (SNZZF) hat eine Webcast-Präsentation seines Q3 2024-Berichts für den 6. November um 15:00 CET angekündigt. Der Bericht wird am selben Tag zuvor veröffentlicht. CEO Philip Siberg wird die Präsentation leiten, gefolgt von einer Q&A-Sitzung, die von Carnegie Investment Bank-Analyst Klas Palin moderiert wird. Die Präsentation wird in englischer Sprache stattfinden und 30 Minuten dauern. Die Teilnehmer können Fragen im Voraus per E-Mail an den Moderator bis zum 6. November um 12:00 CET senden. Die Präsentation wird auf der Website für Investor Relations von Senzime verfügbar sein.

Positive
  • None.
Negative
  • None.

UPPSALA, SWEDEN / ACCESSWIRE / October 30, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) invites investors, analysts, and media to a webcast presentation of the third quarter report for 2024 on November 6, 15:00 CET. The report will be published during the morning of the same day.

The presentation will be held by Philip Siberg, CEO of Senzime, and after the presentation, there will be a Q&A session moderated by Klas Palin, analyst at Carnegie Investment Bank. The presentation will be held in English.

Date and time: Wednesday, November 6, 15:00-15:30 CET

Questions to moderator can be sent by email in advance to klas.palin@carnegie.se before 12:00 CET on Nov 6.

The presentation will be accessible at Senzime's website https://www.senzime.com/investors

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime's TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime's products are commercialized in over 30 countries including direct sales teams in US and Germany.

Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at senzime.com.

Attachments

Invitation to presentation of Senzime's third quarter 2024 report

SOURCE: Senzime



View the original press release on accesswire.com

FAQ

When will Senzime (SNZZF) release its Q3 2024 earnings report?

Senzime will release its Q3 2024 earnings report on the morning of November 6, 2024.

What time is Senzime's (SNZZF) Q3 2024 earnings presentation?

Senzime's Q3 2024 earnings presentation will be held on November 6, 2024, at 15:00-15:30 CET.

How can investors submit questions for Senzime's (SNZZF) Q3 2024 earnings call?

Investors can submit questions via email to klas.palin@carnegie.se before 12:00 CET on November 6, 2024.

SENZIME AB ORD

OTC:SNZZF

SNZZF Rankings

SNZZF Latest News

SNZZF Stock Data

72.86M
57.47M
35.14%
20.04%
Medical Devices
Healthcare
Link
United States of America
Uppsala